若生智能
Drug Database
DR

drospirenone (Slinda / LPRICF113 / LF111)

✓ Approved

HyundaiPharm · ESR1 · 类固醇

什么是 drospirenone？

drospirenone 是一种类固醇，由HyundaiPharm研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Slinda, LPRICF113, LF111
公司HyundaiPharm
药物类别类固醇, 小分子
分子靶点ESR1, ESR2, NR3C2, PGR
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, HyundaiPharm

作用机制

分子靶点

drospirenone 作用于 4 个分子靶点：

ESR1estrogen receptor 1 (ER, ESR)
ESR2estrogen receptor 2 (ESTRB, ER-BETA)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
PGRprogesterone receptor (NR3C3, PR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

drospirenone 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersDysmenorrhoeaPhase II

相关研究文献

PubMedThe journal of obstetrics and gynaecology research2026-06-09

Cerebral Venous Sinus Thrombosis Occurring During Estetrol/Drospirenone Combined Oral Contraceptive Use in a Woman With Multiple Thrombotic Risk Factors: A Case Report.

Nakahara Mariko M, Fuse Atsuhito A, Ito Yosuke Y, Kasahara Hanako H et al.

Estetrol/drospirenone (E4/DRSP) is a combined oral contraceptive noted for its minimal hemostatic impact compared to ethinyl estradiol-based preparations. However, real-world thrombotic risk data in patients with significant comorbidities remain limited. A woman in her early 40s with adenomyosis and menorrhagia was prescribed E4/DRSP. Six weeks later, she developed acute left upper extremity weakness; imaging confirmed superior sagittal sinus thrombosis. She had severe iron deficiency anemia (hemoglobin 6.4 g/dL). Multiple overlapping risk factors-including severe iron deficiency anemia with reactive thrombocytosis, adenomyosis, obesity, hypertension, and age over 40-likely contributed synergistically, and the independent contribution of E4/DRSP cannot be determined. She was treated with anticoagulation and transitioned to relugolix for adenomyosis management. Although E4/DRSP has a favorable coagulation profile, thrombotic risk persists in women with adenomyosis and severe anemia. Pre-prescription assessment including correction of anemia and consideration of estrogen-free alternatives is warranted.

PMID 42261188
阅读全文 →
PubMedResearch in social & administrative pharmacy : RSAP2026-05-25

Real-world pharmacovigilance analysis of drug-induced liver injury in 18-65 years: Based on the FDA adverse event reporting system (FAERS).

Wang Xinlong X, Wang Yingying Y, Hu Ting T, Wang Kaijuan K

Drug-induced liver injury (DILI) in adults aged 18-65 years remains understudied despite its clinical heterogeneity and rising incidence. This study aimed to characterize the epidemiology, associated factors, and drug-specific profiles of DILI in this demographic. Utilizing data from the FDA Adverse Event Reporting System (FAERS) (2004-2024), we analyzed 180,659 DILI cases in patients aged 18-65 years. Four disproportionality methods-Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)-were employed to identify drugs with significant DILI signals. Time-to-onset (TTO) and sex-specific differences were assessed after excluding cases with missing or implausible dates. Twelve drugs exhibited significant DILI signals. Drospirenone; ethinylestradiol (ROR = 16.34, 95%CI: 15.92-16.76), amoxicillin/clavulanic acid (ROR = 6.10, 95%CI: 5.69-6.54), sorafenib (ROR = 5.07, 95%CI: 4.74-5.43), and paracetamol (ROR = 8.76, 95%CI: 8.51-9.01) showed the strongest associations. Analgesics had the shortest median time-to-onset (1 day). Gender subgroup analysis revealed sex-biased hepatotoxicity: 11 drugs met all four criteria in females, with leflunomide (ROR = 4.66, 95%CI: 4.28-5.07) and pembrolizumab (ROR = 4.39, 95%CI: 4.07-4.74) showing strong signals; 14 drugs met the criteria in males, with lamivudine (ROR = 6.87, 95%CI: 6.23-7.58) and amoxicillin/clavulanic acid (ROR = 6.73, 95%CI: 6.08-7.44) among the highest. This analysis identifies antibiotics, immunosuppressants, and hormonal agents as drugs with prominent DILI disproportionality signals in adults aged 18-65 years. The findings advocate for targeted hepatic monitoring and suggest that drug labels could reflect class-specific latency patterns. Sex-specific signal monitoring warrant further investigation.

PMID 42178197
阅读全文 →
PubMedJournal of thoracic disease2026-05-25

Analysis of drug-induced pulmonary embolism risk based on the Food and Drug Administration Adverse Event Reporting System database.

Rui Yang Y, Xiang Beiyi B, Chen Changwen C, Chen Zhe Z et al.

Drug-induced pulmonary embolism (PE) is a serious adverse drug reaction. While the risk of PE associated with specific medications, such as certain antipsychotics, has been preliminarily investigated, the risks of PE across multiple drug classes in real-world settings are yet to be systematically elucidated. This study utilizes the Food and Drug Administration Adverse Event (AE) Reporting System (FAERS) database, covering data from the first quarter of 2004 to the fourth quarter of 2024, with the objective of identifying drug risk signals that are significantly associated with PE. The findings aim to provide a scientific basis for subsequent clinical medication safety. This study retrieved AE reports related to ''PE'' from the FAERS database and conducted a disproportionality analysis using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN). The Preferred Terms (PTs) involved in the study process were standardized using the 27.1 version of the Medical Dictionary for Regulatory Activities (MedDRA). Furthermore, this study systematically classified all drugs involved based on the anatomical therapeutic chemical (ATC) classification standards established by the World Health Organization. This study identified 1,459 drugs associated with the AE of PE, affecting a total of 86,810 patients. Notably, the proportion of female patients was higher than that of male patients. Common drug categories, including antineoplastic and immunomodulating agents, blood and blood-forming organ medications, and nervous system drugs, exhibited strong reporting association signals with PE. The highest number of PE cases was reported for drospirenone/ethinylestradiol, rivaroxaban, and ethinylestradiol/etonogestrel. Through a comprehensive analysis of the FAERS database, this study identified multiple drug categories that exhibit significant positive associations with PE. These findings suggest that clinicians should be vigilant about these potential risk signals, particularly when prescribing long-term treatments to patients with underlying thrombotic risk factors.

PMID 42182709
阅读全文 →
PubMedPakistan journal of pharmaceutical sciences2026-05-22

Hormonal therapies for post-abortion uterine recovery: Comparison of estradiol ± dydrogesterone, transdermal estradiol gel and combined oral contraceptives.

Huang Qin Q, Luo Hai H, Dou Xi X, Wan Xiaoli X et al.

Induced abortion can impair endometrial repair, increasing risks for infertility. This study directly compared three hormonal regimens for enhancing post-abortion uterine recovery. This study aimed to compare the efficacy and safety of different hormonal regimens on uterine recovery following surgically induced abortion. In this randomized controlled trial, 320 patients undergoing induced abortion at Leshan People's Hospital (May 2021 to January 2023) were allocated a computer-generated random number sequence into four groups (n=80 each): Group A received estradiol tablets/estradiol and dydrogesterone tablets, Group B received estradiol gel, Group C received drospirenone and ethiny lestradiol tablets (II) and Group D was a blank control. Primary outcomes included duration of vaginal bleeding, postoperative endometrial thickness, time to first menstruation and incidence of intrauterine adhesions and adverse events. The duration of vaginal bleeding was significantly shorter in the treatment groups (Group A: 4 days [IQR 2-6]; Group B: 4 days [IQR 2-7]; Group C: 3 days [IQR 2-6.5]) compared to the control group (6 days [IQR 4-7]; P<0.05). Endometrial thickness was significantly greater in Group B (0.6 cm [IQR 0.5-0.8]) than in Groups A (0.5 cm [IQR 0.4-0.7]), C (0.4 cm [IQR 0.3-0.5]) and D (0.4 cm [IQR 0.4-0.6]; P<0.05). The time to menstrual resumption was shorter in Groups A (33 days [IQR 31-37]) and C (32 days [IQR 29-35]) compared to Groups B (36 days [IQR 33.5-42]) and D (38 days [IQR 35-44]; P<0.05). No significant differences were observed in postoperative infection or adhesion rates. The incidence of irregular bleeding was higher in Group C (44.4%) than in Group D (13.0%; P<0.05), but all adverse events were self-limiting. This study provides direct comparative evidence that specific hormonal regimens offer distinct benefits for post-abortion recovery. For women seeking contraception through drospirenone and ethinyl estradiol tablets are valuable for shortening bleeding and promoting menstrual regularity. For those with future fertility goals, estradiol gel is valuable for significantly enhancing endometrial regeneration. All regimens demonstrated good safety, enabling personalized clinical decision-making to improve patient outcomes after induced abortion.

PMID 42170985
阅读全文 →
PubMedThe journal of obstetrics and gynaecology research2026-05-19

Safety and Efficacy of a 24-Cycle Administration of a Drospirenone-Only Pill in Japanese Women.

Kitamura Kunio K, Colli Enrico E, Kikuyama Ryoko R, Kurihara Yumiko Y et al.

We conducted a 24-cycle study to evaluate long-term safety of 4 mg of drospirenone (DRSP), a progestin-only pill (POP), for contraception in Japanese women. A multicenter, single-arm 24-cycle study was conducted in women who participated in the 13 cycle study of DRSP. In each cycle, 4 mg of DRSP tablet was administered orally once daily for 24 consecutive days, followed by a placebo tablet for 4 days. In this 24-cycle study, the total number of DRSP exposure cycles was 3878. Fifty-two subjects (100.0%) experienced treatment-emergent adverse events (TEAEs), and 50 (96.2%) experienced adverse drug reactions. All TEAEs were mild or moderate with no severe events. The most common TEAE was intermenstrual bleeding, which occurred in 49 (94.2%) subjects. Although 50.0% of the subjects had risk factors for venous thromboembolism (VTE), no VTE-related TEAEs were observed. No TEAEs led to discontinuation of the study. During 3878 exposure cycles, pregnancy occurred in one subject. The overall Pearl index [95% CI] was 0.34 [0.01, 1.87], and the cumulative pregnancy rate was 0.4%. In this study, the safety of DRSP, the first POP in Japan, was evaluated in Japanese women for 24 cycles. The DRSP-only pill provides a new option for contraception for Japanese women, including those at risk of developing VTE.

PMID 42152782
阅读全文 →
PubMedBMC ophthalmology2026-05-03

Hormone therapy preserves ocular surface integrity following circadian alignment disturbance in menopausal rats.

Acer Semra S, Argun Mehmet M, Özmen Özlem Ö, Açıkgöz Cafer C et al.

This study examines the impact of a light-cycle shift regimen on corneal and conjunctival tissues in menopausal rats and evaluates the protective role of combined hormone therapy. Twenty-four menopausal female albino rats were randomly assigned to three groups (n = 8) following a 10-day acclimatization period. Group 1 (Control+Saline) was maintained under a 12:12 light/dark cycle. Light-cycle shift regimen was induced in Groups 2 and 3 using a rotating 7-day light-exposure sequence repeated over 21 days; this protocol consisted of 24 h of continuous light, 72 h of inverted dark-light timing, and 72 h of standard light-dark conditions. Groups 1 and 2 received saline, while Group 3 received 17β-Estradiol and drospirenone daily via oral gavage. After 31 days, eyes were enucleated for histological and immunohistochemical analyses of corneal, conjunctival, and palpebral tissues, including caspase-3 (Cas-3), tumor necrosis factor-alpha (TNF-α), and PERIOD-2 (PER2) expression. Light-cycle shift regimen (Group 2) significantly increased corneal thickness (p < 0.001), conjunctival inflammation, and vascular congestion, with marked upregulation of Cas-3 and TNF-α and downregulation of PER2. Hormone therapy (Group 3) attenuated these effects, showing reduced corneal edema, diminished inflammatory infiltration, and partial normalization of molecular markers. Shifting light-dark cycles may aggravate inflammatory and apoptotic changes in the ocular surface during menopause. Estrogen-progestin therapy attenuates these alterations by modulating the expression of the circadian-associated protein PER2 and maintaining structural integrity. These findings suggest that hormone therapy may offer potential benefits for preserving ocular surface homeostasis in menopausal women experiencing sleep or circadian rhythm disturbances.

PMID 42069506
阅读全文 →

注册免费账户还可查看另外 1016 篇文献

免费注册查看全部文献 →

了解更多drospirenone